GE HealthCare’s Record Orders Hide PCS Woes and Leadership Flux
Organic orders jump 11%, but margin pressure and a CFO departure cloud the outlook.
GEHC · Earnings Call · 2026-07-29
Order Strength Masks Persistent Margin Pressure
GE HealthCare delivered a standout quarter on the top line, with organic orders up 11.1% and a record backlog of $23.9 billion. As CEO Peter Arduini noted, “We were delighted with our orders performance... broad-based and consistent” — Peter Arduini, President and Chief Executive Officer (CEO) · 2026-07-29. The strength was led by new product momentum, particularly in advanced imaging and ultrasound, with Al enabled systems like the Vivid Pioneer delivering higher gross margins. However, the quarter also exposed continued weakness in Patient Care Solutions (PCS), which saw organic revenue decline 13.5% and segment EBIT turn negative. Management initiated a strategic review of the division, including options from continued ownership to a sale. This came alongside a CFO transition, with Jay Saccaro leaving for an external opportunity and George Newcomb appointed interim CFO.Innovation Cycle Provides a Bridge
The order strength gives confidence in the second half and into 2027. Jay Saccaro explained the bridge: “...robust orders performance, 11% on a quarter basis... on a two-year stack, over 7% order growth... really sets us up well heading into the second half” — Jay Saccaro, Vice President and Chief Financial Officer (CFO) · 2026-07-29. New products like the photon-counting CT (Photonova Spectra) are poised to contribute, while Flyrcado (a radiopharmaceutical) continues its ramp, with weekly doses up ~40% since April. The company's platform approach is driving margin expansion in newer products, but inflation—particularly from memory chips and fuel—remains a headwind. Jay called out “...inflation was about 120 basis points headwind, which was in line with our expectations” — Jay Saccaro, Vice President and Chief Financial Officer (CFO) · 2026-07-29.Financials: Margin Trouble Below the Top Line
Revenue grew 3.5% organically, but adjusted EBIT margin fell 40bps to 14.2%. Gross margin slipped to 38.5% (-3.6pp y/y), per the fundamentals data. Free cash flow was just $68M, as working capital absorbed tariff refunds. Notably, net debt rose to ~$7.9B, reflecting the Intelerad acquisition. The tariff refund provided $23M of EBIT relief, but management kept full-year EPS guidance unchanged at $4.80-$5.00, citing uncertainty on oil and memory costs.What's Next: De-risking and New Leadership
The PCS strategic review introduces optionality, but also uncertainty. As Peter stated,The unexpected CFO departure adds leadership risk, though the team emphasized continuity. Prior commentary on PCS had already flagged challenges; in the April call, Peter admitted, “We weren't pleased with the decline in this magnitude, and we're heavily focused on mitigation actions.” — James Saccaro, Vice President and Chief Financial Officer · 2026-04-29 And from the October call, Jay had echoed, “We were disappointed with PCS performance in the third quarter.” — James Saccaro, Vice President and CFO · 2025-10-29 Beyond PCS, the company is betting on a slower recovery in China and a challenging macro. Yet the order book suggests healthcare capital demand remains robust, and the innovation pipeline—especially in AI-driven imaging—offers a credible path to mid-single-digit growth and margin expansion over the medium term....we're looking at multiple alternatives... is this business better parked with someone else? Over the coming quarters, it will be about improvement of the business while simultaneously looking at those options.